All age groups in the United States are experiencing a "high severity" of influenza cases among all age groups for the first ...

The volume of recent flu infections and related hospitalizations is higher than what Sonoma County epidemiologists have ...

Dr. Michael Reihart, with Penn State Health, also explained who's most at risk for severe illness and how effective this year's vaccine is.

As we navigate through flu season and the ongoing challenges of respiratory illnesses, it’s crucial to prioritize our health and well-being. One of the most effective ways to do this ...

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Here are four more respiratory illness updates: Nearly 1.7% of all deaths nationwide were attributed to flu, compared to approximately 1.5% from COVID-19. Influenza test positivity rose to 31.6%, ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Dr. Smith is the president of the Tennessee Chapter of the American Academy of Pediatrics.

The biotech giant reported a bigger-than-expected quarterly loss. Finance chief James Mock attributed the loss to a scale down.

The U.S. has seen earlier and more intense surges of the flu and RSV this year than is typical, pediatrician Dr. Ryan Fulton ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...